295 reports of suspected side effects of implants in 2023 In 2023, 295 individuals reported one or more suspected side effects of implants to RIVM’s Dutch Reporting Centre for Adverse Effects of Medical Implants (MEBI).
RIVM European Reference Lab for vector-borne infections The European Commission (EC) has designated RIVM as the current European Reference Lab (EURL) for vector-borne viral pathogens.
Menno de Jong appointed director of RIVM Centre for Infectious Disease Control Starting 1 May 2024, Professor Menno de Jong will take on the role of director of RIVM’s Centre for Infectious Disease Control (CIb) . He succeeds Jaap van Dissel, who is retiring in April 2024.
Number of tuberculosis patients in the Netherlands increased in 2023 compared to 2022 In 2023, 710 people in the Netherlands were diagnosed with tuberculosis (TB). This was 12 per cent more than in 2022, when there were 634. In 2023, 471 patients had pulmonary TB. Of these 417 patients, 213 had open TB – the most contagious type.
National cervical cancer screening campaign under way Today sees the kick-off of the national campaign: Let’s talk about cervical cancer – have you #done the smear test or self-test yet? This marks the first time that RIVM, Bevolkingsonderzoek Nederland and the KWF Dutch Cancer Society are launching a joint campaign to call attention to cervical cancer screening.
RIVM identifies three major challenges for public health and healthcare in period to 2050 The Dutch public health and healthcare will face three crucial challenges in the period to 2050. This is according to RIVM’s preview of the Dutch Public Health Foresight Study 2024.
Self-sampling device to be sent automatically, making it easier to take part in cervical cancer screening From the first week of July, every woman turning 30 will receive a self-sampling device with their invitation for cervical cancer screening. Participants can use this device to collect their own vaginal material.
Breast implants can cause health problems even five years or more after placement Over the past 5 years, the Dutch reporting and expertise centre for adverse effects of medical implants (MEBI) has received 977 reports of health problems related to breast implants. An analysis by RIVM has shown that 39% of the reported health problems started 5 or more years after the implant’s placement.
No indication that investigated mesh implants used to treat pelvic organ prolapse are unsafe RIVM has conducted a laboratory study into six mesh implants from different manufacturers used in the Netherlands in 2018. The study revealed no indication that these products are unsafe for patients.
Number of tuberculosis patients in the Netherlands decreased slightly in 2022 compared to 2021 The number of people with tuberculosis (TB) in the Netherlands decreased slightly in 2022. In 2022, there were 635 TB patients in the Netherlands. This is six per cent fewer than in 2021, when there were 673 patients.